Not So Different: A Podcast From The Center For Biosimilars
S2 Ep29: Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:10:03
- Mas informaciones
Informações:
Sinopsis
Last month, the European Commission authorized a subcutaneously administered formulation of biosimilar infliximab CT-P13 for the treatment of rheumatoid arthritis. When the drug launches in the European Union, it will be first infliximab to be available in a subcutaneous formulation. This week on the podcast, we’re speaking about this new product with Mike An, head of the sales and operations division at Celltrion Healthcare.
